Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
IPO Year:
Exchange: NASDAQ
Website: iovance.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/29/2024 | $19.00 → $10.00 | Overweight → Neutral | Piper Sandler |
11/20/2023 | $12.00 | Buy | Goldman |
9/18/2023 | $40.00 → $18.00 | Overweight | Barclays |
5/30/2023 | $11.00 → $17.00 | Equal Weight → Overweight | Wells Fargo |
3/27/2023 | $11.00 | Equal Weight | Wells Fargo |
1/27/2023 | $11.00 → $14.00 | Neutral → Overweight | Piper Sandler |
12/9/2022 | $20.00 → $6.00 | Buy → Neutral | Goldman |
10/31/2022 | Neutral | Guggenheim | |
8/18/2022 | $14.00 | Equal Weight | Wells Fargo |
2/25/2022 | $35.00 → $30.00 | Outperform | Baird |
8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
S-8 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
S-8 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
10-Q - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
DEFA14A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
10-Q - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
SAN CARLOS, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on August 15, 2024 (the "Date of Grant"), the Company approved the grant of inducement stock options and restricted stock units covering an aggregate of 289,710 shares of Iovance's common stock to twenty-four new, non-executive employees. The awards were granted under Iovance's 2021 Inducement Plan, which was adopted on September 22, 2021 and amended on January 12, 2022, March 13,
Strong Momentum Continues for Amtagvi™ (Lifileucel) U.S. Launch with $31.1 Million in Total 2Q24 Revenue Total Product Revenue Guidance of $53-$55 Million for 3Q24, $160-$165 Million for FY24, and $450-$475 Million for FY25 SAN CARLOS, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported second quarter and first half 2024 financial results and corporate updates. Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, "The first
SAN CARLOS, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter and first half 2024 financial results on Thursday, August 8, 2024. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/uhudv42k/. The live and archived webcast can be accessed in the Investors section of the Company's
SAN CARLOS, Calif., July 19, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on July 18, 2024 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 106,010 shares of Iovance's common stock to nineteen new, non-executive employees. The awards were granted under Iovance's 2021 Inducement Plan, which was adopted on September 22, 2021 and amended on January 12, 2022, March 13, 2023, and February 26, 2024 and
First of Multiple Planned Global Submissions for Lifileucel in 2024 and 2025 Key Step in Global Expansion to Address >20,000 Patients Annually with Previously Treated Advanced Melanoma SAN CARLOS, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer, submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for lifileucel, a TIL cell therapy, for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a P
SAN CARLOS, Calif., June 21, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on June 20, 2024 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 187,650 shares of Iovance's common stock to forty-three new, non-executive employees. The awards were granted under Iovance's 2021 Inducement Plan, which was adopted on September 22, 2021 and amended on January 12, 2022, March 13, 2023, and February 26, 2024
SAN CARLOS, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences and events: TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHAFireside Chat: May 28, 2024 at 3:00 p.m. ETVirtual Iovance ASCO Investor/Analyst EventPresentation and Key Opinion Leader Panel Discussion: May 31, 2024 at 7:15 p.m. ETChicago, IL and Virtual Jefferies Global Healthcare ConferenceFireside Chat: June 6, 2024 at 9:30
Lifileucel TIL Cell Therapy in Combination with Pembrolizumab DemonstratesDeep, Durable Responses in Frontline Advanced Melanoma Patientsin IOV-COM-202 Clinical Study ASCO Oral Presentation to Highlight 65% Objective Response Rate (ORR) and 30% Complete Response Rate Nearly All Responses Remain Ongoing at a Median Follow-up of 21.7 Months in the Oral Presentation Data in Published Abstract and Upcoming Oral PresentationStrongly Support Ongoing TILVANCE-301 Phase 3 Trial SAN CARLOS, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating
SAN CARLOS, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on May 16, 2024 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 153,930 shares of Iovance's common stock to thirty new, non-executive employees. The awards were granted under Iovance's 2021 Inducement Plan, which was adopted on September 22, 2021 and amended on January 12, 2022, March 13, 2023, and February 26, 2024 and pro
Strong Momentum for Amtagvi™ (Lifileucel) U.S. Launch Following U.S. Food and Drug Administration (FDA) Approval 100+ Amtagvi Patients Enrolled Across More Than 40 Current Authorized Treatment Centers (ATCs), with ~50 Total ATCs On Track by End of May and 70+ Total ATCs by Year-End 2024 Amtagvi Regulatory Submissions on Track in the European Union (EU), United Kingdom (UK), and Canada in 2024 SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported first quarte
For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B
SC 13D/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)
SC 13G - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)
SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)
SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)
SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)
SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)
SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)
SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)
SC 13G - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)
SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume BSX PUT SWEEP BEARISH 08/16/24 $75.00 $68.9K 5.5K 2.1K MRNA CALL SWEEP NEUTRAL 11/15/24 $170.00 $121.
Iovance Biotherapeutics's (NYSE:IOVA) short percent of float has risen 3.31% since its last report. The company recently reported that it has 56.42 million shares sold short, which is 22.5% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.68 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Shor
U.S. stocks were mostly higher, with the Dow Jones index gaining around 100 points on Thursday. Shares of Methode Electronics, Inc. (NYSE:MEI) rose sharply during Thursday's session after the company reported better-than-expected fourth-quarter sales results. Methode Electronics reported a fourth-quarter fiscal 2024 net sales decline of 7.9% year-on-year to $277.30 million, beating the analyst consensus estimate of $264.04 million. Adjusted EPS loss of 23 cents missed the analyst consensus loss estimate of 20 cents, according to data from Benzinga Pro. Methode Electronics shares surged 29.4% to $12.22 on Thursday. Here are some other big stocks recording gains in today’s session.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and maintains $32 price target.
JMP Securities analyst Reni Benjamin maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Market Outperform and lowers the price target from $25 to $23.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and maintains $32 price target.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and maintains $32 price target.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume PFE CALL SWEEP BULLISH 05/31/24 $29.00 $50.3K 6.8K 8.2K SRPT CALL TRADE BULLISH 06/21/24 $110.00 $1.3
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stock is trading higher. The company recently announced updated clinical data for treating frontline advanced melanoma. What Happened: On Thursday, Iovance revealed updated clinical findings for lifileucel in conjunction with pembrolizumab as a treatment for frontline advanced melanoma, as well as implementation data, to be presented at the 2024 ASCO Annual Meeting. Results from the clinical trial, specifically IOV-COM-202 trial’s Cohort 1A, were published in an abstract and showcased promising outcomes in frontline advanced melanoma patients new to immune checkpoint inhibitor therapy. The findings from the 23 patients include a 65.2% ove
Strong Momentum Continues for Amtagvi™ (Lifileucel) U.S. Launch with $31.1 Million in Total 2Q24 Revenue Total Product Revenue Guidance of $53-$55 Million for 3Q24, $160-$165 Million for FY24, and $450-$475 Million for FY25 SAN CARLOS, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported second quarter and first half 2024 financial results and corporate updates. Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, "The first
SAN CARLOS, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter and first half 2024 financial results on Thursday, August 8, 2024. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/uhudv42k/. The live and archived webcast can be accessed in the Investors section of the Company's
Strong Momentum for Amtagvi™ (Lifileucel) U.S. Launch Following U.S. Food and Drug Administration (FDA) Approval 100+ Amtagvi Patients Enrolled Across More Than 40 Current Authorized Treatment Centers (ATCs), with ~50 Total ATCs On Track by End of May and 70+ Total ATCs by Year-End 2024 Amtagvi Regulatory Submissions on Track in the European Union (EU), United Kingdom (UK), and Canada in 2024 SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported first quarte
SAN CARLOS, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2024 financial results on Thursday, May 9, 2024. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/m4tigan7. The live and archived webcast can be accessed in the Investors section of the Company's website, I
SAN CARLOS, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its fourth quarter and full-year 2023 financial results on Wednesday, February 28, 2024. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. To participate in the live conference call Q&A, please register at https://register.vevent.com/register/BI289df7d30f474a72a72e1c4f7a754c92. To listen to the live or archived audio webcast, please r
SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast to discuss the FDA approval announced earlier today at 4:15 p.m. ET, February 16, 2024. To participate in the conference call Q&A and live audio webcast, please register at https://register.vevent.com/register/BI0633b8a73e8b4c578bfed2a8ef37003e. To listen to the live or archived webcast, please register at https://edge.media-server.com/mmc/p/uqbbcfz4/. The live and archived webcast
SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its third quarter and year-to-date 2023 financial results on Tuesday, November 7, 2023. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. To participate in the conference call Q&A and live audio webcast, please register at https://register.vevent.com/register/BIfd1787749ef747f19a491cb371d60fab. To listen to the live or archived webcast,
SAN CARLOS, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter 2023 financial results on Tuesday, August 8, 2023. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. To participate in the conference call and live audio webcast, please register at https://register.vevent.com/register/BI83559f749d674b71bae2cbaeb65d484b. To listen to the live webcast, please register at https://edge.m
SAN CARLOS, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host an investor conference call and webcast to discuss lifileucel TIL therapy and the emerging melanoma treatment landscape on June 26, 2023, at 5:00 p.m. ET. During the one-hour event, the Iovance leadership team will provide a brief recap of the C-144-01 trial and clinical data, defined regulatory pathway, and pre-commercial activities for lifileucel in advanced post-anti-PD-1 melanoma. A multidisciplinary panel of key opin
First Biologics License Application (BLA) Submission Completed in March 2023 Commercial Readiness Activities on track to Support Potential Commercial Launch of Lifileucel in 2023 SAN CARLOS, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T-cell-based cancer immunotherapies (tumor infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today reported first quarter 2023 financial results and corporate updates. Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, "Since the beginning of 2023, we have completed our first BLA for lifileucel i
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
Piper Sandler downgraded Iovance Biotherapeutics from Overweight to Neutral and set a new price target of $10.00 from $19.00 previously
Goldman initiated coverage of Iovance Biotherapeutics with a rating of Buy and set a new price target of $12.00
Barclays reiterated coverage of Iovance Biotherapeutics with a rating of Overweight and set a new price target of $18.00 from $40.00 previously
Wells Fargo upgraded Iovance Biotherapeutics from Equal Weight to Overweight and set a new price target of $17.00 from $11.00 previously
Wells Fargo resumed coverage of Iovance Biotherapeutics with a rating of Equal Weight and set a new price target of $11.00
Piper Sandler upgraded Iovance Biotherapeutics from Neutral to Overweight and set a new price target of $14.00 from $11.00 previously
Goldman downgraded Iovance Biotherapeutics from Buy to Neutral and set a new price target of $6.00 from $20.00 previously
Guggenheim initiated coverage of Iovance Biotherapeutics with a rating of Neutral
Wells Fargo resumed coverage of Iovance Biotherapeutics with a rating of Equal Weight and set a new price target of $14.00
Baird reiterated coverage of Iovance Biotherapeutics with a rating of Outperform and set a new price target of $30.00 from $35.00 previously
STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial Officer (CFO), effective immediately. As a member of the Executive Leadership Team, Mr. Maynard will lead the Company's financial operations. "Ryan's deep financial leadership experience will be instrumental to the execution of Cara's long-term growth strategy as we continue to maximize the KORSUVA™ (difelikefalin) injection launch and advance our oral difelikefalin pipeline to establish our position
SAN CARLOS, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today announced the appointment of Wendy L. Dixon, Ph.D., to the company's Board of Directors, effective June 10, 2022. Dr. Dixon has more than 40 years of experience in the biopharmaceutical industry, building and leading organizations and launching and growing more than 20 major global pharmaceutical products, including many highly successful multibillion dollar global brands. Iain Dukes, D. Phil., Chairman of the Board of Direc
REDWOOD CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers, announced the appointment of Franco Valle as Chief Financial Officer. Mr. Valle is an accomplished financial expert who brings extensive experiences to Biomea, in particular with building the necessary infrastructure to support clinical and operational growth within biotech companies. Mr. Valle will also assume the role of Principal Financial Officer and Principal Accounting Officer upon joining. Recently, Mr. Valle se
SAN CARLOS, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the appointment of Igor Bilinsky, Ph.D., as Chief Operating Officer, effective today. Dr. Bilinsky brings more than 20 years of biotechnology industry experience as a senior executive and consultant, including public companies. “I am pleased to welcome Igor to Iovance and look forward to his contributions while we advance our TIL cell therapy pipeline,” stated Maria Fardis, Ph.D., President and Chief Executive Officer of Iovance Biotherapeutics. “Through his experience in several senior